Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease

• Published in: Journal of Korean medical science Vol. 25; no. 7; pp. 1029 - 1033
• Main Authors: Ryu, Sang-Young, Kim, Kidong, Kim, Younha, Park, Sang-Il, Kim, Beob-Jong, Kim, Moon-Hong, Choi, Seok-Cheol, Lee, Eui-Don, Lee, Kyung-Hee, Kim, Byung Il
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Academy of Medical Sciences 01.07.2010; 대한의학회
• Subjects: Adult; Aged; Endometrial Neoplasms - diagnosis; Endometrial Neoplasms - diagnostic imaging; Endometrial Neoplasms - pathology; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Recurrence, Local - diagnosis; Neoplasm Recurrence, Local - diagnostic imaging; Neoplasm Recurrence, Local - pathology; Original; Positron-Emission Tomography - methods; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; 의학일반; Recurrence; Positron-Emission Tomography; Endometrial Neoplasms
• ISSN: 1598-6357; 1011-8934; 1598-6357
• DOI: 10.3346/jkms.2010.25.7.1029

This study assessed the feasibility of F-18-fluorodeoxyglucose positron-emission tomography ((18)F-FDG PET) in the post-therapy surveillance for patients with endometrial cancer showing no evidence of disease (NED). From April 1997 to June 2007, 127 patients with endometrial cancer showing NED were performed (18)F-FDG PET scan. The feasibility of (18)F-FDG PET for the early detection of recurrence in patients with endometrial cancer was evaluated retrospectively. Of the 127 patients, 32 patients showed positive lesions on (18)F-FDG PET scan. Nineteen (19/127 cases, 15%) of them were confirmed to have a recurrence clinically or histologically. The sensitivity, specificity and positive and negative predictive value of (18)F-FDG PET for detecting recurrences in patients with endometrial cancer were 100%, 88%, 59% and 100%, respectively. In conclusion, (18)F-FDG PET may be a useful method for the post-therapy surveillance in patients with endometrial cancer.